natgillin/translations-raw huggingface dataset:
a third software module executable by the processor and the memory, the third software module configured to compare the attribute of the parsed field to a valid characteristic of a valid corresponding field specified by a portable executable file format specification; a fourth software module executable by the processor and the memory, the fourth software module configured to determine if the attribute of the parsed field matches the valid characteristic of the valid corresponding field specified by the portable executable file format specification, wherein determining if the attribute of the parsed field matches the valid characteristic of the valid corresponding field specified by the portable executable file format specification further includes determining if the attribute of the parsed field is valid for a predetermined operating system; 
Sustav koji sadrži: procesor; memoriju spojenu sa procesorom; prvi softverski modul izvršiv putem procesora i memorije, prvi softverski modul konfiguriran da identificira (100) nevažećeg polje prijenosne izvršne datoteke uspoređivanjem atributa polja spomenute prijenosne izvršne datoteke sa važećim karakteristikama važećih odgovarajućih polja kako je navedeno u specifikacijama formata prijenosne izvršne datoteke; drugi softverski modul izvršiv putem procesora i memorije, drugi softverski modul konfiguriran da odredi (102) vjerojatnost popravka nevažećeg polja prijenosne izvršne datoteke utvrđujući (114) broj i karakteristike
The system of claim 9, wherein the liquid fraction from the high temperature/high pressure separator is fed to the atmospheric fractionation unit. 
Sustav u skladu s patentnim zahtjevom 29, naznačen time, da se tekuća frakcija iz separatora (40) visoke temperature / visokog pritiska dovodi u jedinicu za atmosfersko frakcioniranje (54).
The solution of nebivolol hydrochloride—hypromellose was adsorbed onto the blend fluidized in the container of the fluid Bed Processor by top spay process. 
Otopina nebivolol hidroklorida - hipromeloze adsorbirana je na mješavinu fluidiziranu u posudi Fluid Bed Procesora postupkom top spray.
The antisense oligomer according to claim 3, or pharmaceutically acceptable salt or hydrate thereof, wherein the 5′ end of the antisense oligomer is any one of the groups of chemical formulae (1) to (3) below: 
Protusmjerni oligomer u skladu s patentnim zahtjevom 6 ili 7, naznačen time što je na 5′ kraju bilo koja od skupina s kemijskim formulama (1) do (3), niže: [image] .
In another preferred embodiment of the pharmaceutical methods of the invention, the CD19xCD3 bispecific single chain antibody construct is to be administered in a daily dose of 10µg to 100µg per square meter patient body surface area. 
Konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt treba primijeniti u dnevnoj dozi od 10 ug do 100 ug/m' tjelesne površine pacijenta.
A coordinate system has been defined for the ROV 1, the axes of which intersect the ROV's centre of gravity (CG; see also figures 20 and 21), and where the x axis defines a roll axis; the y axis defines a pitch axis; and the z axis defined a yaw axis. 
Podvodno vozilo prema zahtjevu 1, pri čemu je prvi par elemenata za uravnoteženje (10a, b) smješten u ravnini paralelnoj s ravninom y-z vozila i udaljen je od težišta vozila (CG); dok je drugi par elemenata za uravnoteženje (124, b) smješten u ravnini x-y i uzduž x osi.
propagation of an enzyme producing microorganism, and production of enzymes by the enzyme producing microorganism. The process according to claim 1, wherein a part of the enzymatically hydrolysed lignocellulosic material and a part of the lignocellulosic material is used in the propagation of the enzyme producing microorganism and/or the production of enzymes by the enzyme producing microorganism. 
razmnožavanje gljivice i proizvodnje enzima pomoću gljivice, pri čemu se dio enzimski hidroliziranog lignoceluloznog materijala dio prethodno obrađenog lignoceluloznog materijala koristi u razmnožavanju gljivice i/ili proizvodnji enzima pomoću gljivice i pri čemu se enzimi proizvedeni s gljivicom koriste u enzimskoj hidrolizi.
In one aspect of the invention, the chemically modified glycosaminoglycan has a low, controlled content of chemically modified glucosamine residues as a result of the process steps of its manufacturing. 
HR P20180124 T1 PATENTNI ZAHTJEVI Kemijski modificiran glikozaminoglikan, naznačen time da se glikozaminoglikan bira iz skupine koja se sastoji od heparina i heparan sulfata, te što kemijski modificiran glikozaminoglikan ima:
the RNase is a human RNase, such as a human pancreatic RNase 1; and/or the DNase is selected from the group consisting of a Type 1 human DNase, a human DNase 1L3, or human TREX1; and/or 
(a) RNaza je ljudska RNaza, kao što je ljudska RNaza 1 gušterače; i/ili (b) DNaza je odabrana iz skupine koja se sastoji od ljudske DNaze tip 1, ljudske DNaze 13, ili ljudskog TREX1; i/ili
a pharmaceutically acceptable salt, solvate or hydrate thereof. 
C2.s cikloalkil, ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat.
constructing a prediction block using the intra prediction mode; inversely quantizing a received residual signal using a quantization parameter to create a quantized block and inversely transforming the quantized block to create a residual block; and 
modul (240) za intrapredikciju konfiguriran da rekonstruira intrapredikcijski režim i da kreira predikcijski blok tekućeg bloka ili podbloka tekućeg bloka;
fed under pressure to a second filter 14b of the second station 15b, with minimum passage aperture of 40 micron; 
- < dopremi se pod tlakom do drugog filtral4b druge stanice 15b, s minimalnim otvorom prolaza od 40 mikrona;
The indexed drug containment device (24) of any of claims 1-3, wherein the first and second openings (36, 36') are selected from a groove, slot, channel, aperture or hole, and the first and second keys (18, 20) are selected from a tongue, prong, post, ridge, protrusion or rail. 
Indeksirani uređaj za ograničavanje sadržaja lijeka (24) prema bilo kojem od zahtjeva 1-3, naznačen time da su prvi i drugi otvor (36, 36') odabrani od žljeba, proreza, kanala, otvora 1li provrta, a prvi 1 drugi ključevi (18, 20) su odabrani od jezička, kraka, poluge, grebena, izbočenja ili vodilice.
use of the compound of the aforementioned (1) for manufacture of an angiotensin II antagonist; 
14. Uporaba, naznačena time, da se koristi spoj prikazan formulom (1)
and and an M72 component; wherein the M72 component has the sequence of SEQ ID No: 25. 
HR P20181353 T1 i i M72 sastavni dio; gdje M72 sastavni dio ima slijed SEQ ID No: 25.
The liner of claim 22, wherein the wrapped layer of impermeable material about the impregnated tubular member is edged sealed. 
Materijal za sanaciju prema zahtjevu 22, naznačen time da je sloj omotača od nepropusnog materijala koji je omotan oko impregnirajućeg cjevastog elementa, rubno zabrtvljen.
A method which, according to claim 1, is characterized by the detection of the hole Serum amyloid P-component (SAP, SAMP, SwissProt No: P02473) or fragments of it's amino acid sequence or of the modified protein as result of post-translation modifications. 
Metoda koja je, prema zahtjevu 1, naznačena detekcijom cijelog seruma amiloidne komponente P (SAP, SAMP, SwissProt br. PO2743) ili modificiranog proteina kao posljedice posttranslacijskih modifikacija.
the single rearranged human immunoglobulin light chain variable region gene sequence comprises the Yk1-39/JK gene sequence comprising a replacement of at least one non-histidine codon with a histidine codon designed to express a histidine 
(1) jedna preuređena genska sekvenca varijabilne regije humanog imunoglobulinskog lakog lanca sadrži Vx139/JK gensku sekvencu koja se sastoji od zamjene najmanje jednog nehistidinskog kodona histidinskim kodonom dizajniranim da izražava histidin
The non-aqueous ink jet ink composition according to claim 1, characterized in that the pH of a water extract of the non-aqueous ink jet ink composition according to claim 1 is 6.0 to 10.0. 
Nevodeni sastav inkjet tinte u skladu s patentnim zahtjevom 1, karakteriziran na način da pH vodenog ekstrakta nevodenog sastava inkjet tinte u skladu s patentnim zahtjevom 1 iznosi 6.0 do 10.0.
The built-in sun-shading device to be built into hollow glass in claim 1, which is further characterized in that: the sun-shading mechanism further comprises a pleated blind or a honeycomb blind. 
Integrirani uređaj za zaštitu od sunca koji se ugrađuje u šuplje staklo u skladu s patentnim zahtjevom 1, naznačen time, da mehanizam za zaštitu od sunca nadalje sadržava plisirane rolete ili sjenila u obliku saća.
a C1-6 alkoxy-carbonyl group optionally having 1 to 3 substituents selected from a nonaromatic heterocyclic group optionally having 1 to 3 substituents selected from a C1-6 alkyl group and oxo group or 
C1-6 alkoksi-karbonil skupina koja opcionalno ima 1 do 3 supstituenta odabrana iz nearomatske heterociklične skupine koja ima opcionalno 1 do 3 supstituenta odabrana iz C1-6 alkilne skupine i okso skupine; ili
providing a second guide positioned adjacent to the door; 
drugu vodilicu (804) smještenu susjedno vratima (704);
The dosage form of claim 4, wherein the content of rasagiline is 0.5 mg or 1.0 mg, and which comprises mannitol, colloidal silicon dioxide, starch NF, pregelatinized starch, stearic acid, talc, hypromellose, methacrylic acid ethyl acrylate copolymer, talc extra fine, and triethyl citrate. 
Oblik doziranja prema patentnom zahtjevu 2, naznačen time, da je sadržaj rasagilin citrata od 0,74 mg do 3,63 mg i koji uz rasagilin citrat sadrži manitol, koloidni silicijev dioksid, škrob NF, prethodno želatinirani škrob, stearinsku kiselinu, talk, hipromelozu, kopolimer metakrilna kiselina - etil akrilat, ekstra fini talk i trietil citrat,
MH+ and [M-H]− refer to monoisotopic molecular weights. 
MH" i [M-H] se odnose na monoizotopne molekulske mase.
A nitrating mixture is prepared by adding, slowly and with caution at 0 °C, 1.8 mL of 60% HNO3 to a mixture of 7.5 mL of acetic anhydride and 12.5 mL of acetic acid. 
R=COCH, 14 R=NO, Smjesu za nitriranje se pripravi polaganim i opreznim dodavanjem pri 0C 1,8 mL 60%-tne HNO; u mješavinu od 7,5 mL octenog anhidrida i 12,5 mL octene kiseline.
Based on the MW of monomeric IL-2 (15.3kDa for native IL-2), the molecular weight of an aggregate can be converted into an inferred number of IL-2 monomers per aggregate. 
Bazirano na MW od monomernog IL-2 (15,3kDa za prirodni IL-2), molekularna težina agregata može se konvertirati u izvedeni broj IL-2 monomera po agregatu.
Use of the fungicidal composition according to any one of claims 1 to 4 in the control of grape downy mildew, wheat rust, potato late blight, wheat powdery mildew, tomato grey mold or grape anthracnose. 
Primjena fungicidne kompozicije u skladu sa patentnim zahtjevom 8 u kontroli plamenjače (down mildew) grožđa, hrđe pšenice, kasne paleži krumpira, pepelnice pšenice, sive truleži rajčice ili antraknoze grožđa.
A pharmaceutical formulation comprising an anti-IL-17 antibody at a concentration in the range of 80 mg/mL to 150 mg/mL, citrate buffer at a concentration of 20 mM, sodium chloride at a concentration of 200 mM, polysorbate-80 at a concentration in the range of 0.02% (w/v) to 0.03% (w/v), and pH at 5.7, wherein the anti-IL-17 antibody comprises an antibody with a light chain (LC) and a heavy chain (HC), wherein said LC is the amino acid sequence of SEQ ID NO: 4 and said HC is the amino acid sequence of SEQ ID NO: 5. 
Farmaceutska formulacija, naznačena time što sadrži protutijelo protiv IL-17 u rasponu koncentracija od 80 mg/ml do 150 mg/ml, citratni pufer u koncentraciji od 20 mM, natrijev klorid u koncentraciji od 200 mM, polisorbat-80 u rasponu koncentracija od 0,02% (tež./vol.) do 0,03% (tež./vol.), te pH od 5,7, gdje protutijelo protiv IL-17 sadrži protutijelo s lakim lancem (LC) i teškim lancem (HC), gdje navedeni LC ima aminokiselinski slijed sa SEQ ID NO: 4, a navedeni HC ima aminokiselinski slijed sa SEQ ID NO: 5.
Z is —(CH)n1— or the bivalent radical defined above under b) n1, n2, R2 and X1 are as defined above; 
Zje ili dvovalentni radikal gore definiran pod b) ni, 1, Rži X, jesu kao što su gore definirani, 2 (CH), o In
hydrolyzing the product of step (b) to form the hydroxymethyl oxazolidinone compound of formula V 
Cc) hidroliziranje proizvoda iz koraka (b) za tvorbu hidroksimetil-oksazolidinona spoja formule V:
treating 1-methyl-1H-pyrazol-5-amine with a strong base in an aprotic solvent at reduced temperature and adding the compound of formula I to afford IX; and, 
OSi(R2), (g) obrada 1-metil-1H-pirazol-5-amina s jakom bazom u aprotičkom otapalu na smanjenoj temperaturi 1 dodavanje spoja formule I, kako bi se dobio IX; i go"
In the accommodation 112 there is arranged, along a vertical plane, lever 114, roughly in the shape of an L, that forms one of the main features if the present invention. 
U uređaju 112 nalazi se, uz okomitu ravninu, poluga 114, uglavnom oblika slova L, koja je jedna od osnovnih karakteristika ovog izuma.
wherein Q1 represents an arylene group or 5- to 6-membered heteroarylene group, Q2 represents an aromatic group or a 5- to 6-membered ring heterocyclic group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, hydroxyl group, C1-C4 alkyl group, halogeno C1-C4 alkyl group, C1-C4 alkoxyl group and halogen C1-C4 alkoxyl group, 
Z predstavlja aromatsku skupinu ili 5- do 6-eročlanu heteroaromatsku prstenastu skupinu od kojih svaka može biti supstituirana skupinom/skupinama izabranim iz grupe koju čine atom halogena, C,-Cs alkil skupina, halogeno C;- Cg alkil skupina, C,-Cg alkoksil skupina i halogeno C;-Cg alkoksil skupina, ili njegovu farmaceutski prikladnu sol kao djelatnu tvar, i gdje se otopina kapa u oko.
A tablet comprising crystalline apixaban particles and a pharmaceutically acceptable diluent or carrier, wherein the tablet is obtainable by a process of manufacturing apixaban tablets, comprising the steps of: 
Proces proizvodnje tableta apiksabana, pri čemu svaka tableta ima kompoziciju koja sadrži do 5 mg čestica kristalnog apiksabana i farmaceutski prihvatljiv razrjeđivač ili nosač, koji obuhvaća korake:
ii) a mixture of a bile salt and a biologically active polypeptide. 
terapeutski učinkovitu količinu biološki aktivnog polipeptida; komponentu šumeće pomoćne tvari; i žučnu sol.
The peptide complex of any one of paragraphs 1-17, wherein the peptide complex is conjugated to a polyethylene glycol (PEG) moiety, human serum albumin (HSA), an HSA-binding domain, an antibody or fragment thereof, hydroxyethyl starch, a proline-alanine-serine multimer (PASylation), a C12-C18 fatty acid, or polysialic acid. 
Peptidni kompleks prema bilo kojem od zahtjeva 1-10, pri čemu je peptidni kompleks konjugiran sa ostatkom polietilen glikola (PEG), albuminom iz humanog seruma (HSA), ili HSA-vezujućim područjem, antitijelom ili njegovim fragmentom, hidroksietil škrobom, prolin-alanin-serin multimerom (PASilacija), C12-C18 masnom kiselinom, ili polisijalinskom kiselinom.
By way of illustrations, but not as limitations, embodiments of lyophilised formulations according to this invention are reconstituted with a volume of water. 
Radi ilustracije, ali ne kao ograničenje, varijante liofiliziranih oblika prema ovom izumu su rekonstruirane sa zapreminom vode.
The composition according to claim 2, wherein L-cysteine is present in a concentration of 0.5-4 mg/ml. 
Pripravak u skladu s patentnim zahtjevom 2, naznačen time što je l-cistein prisutan u koncentraciji od 0,5-4 mg/ml.
The animal of claim 8, wherein the human portion of the chimeric human/mouse MHC II a polypeptide is encoded by a human HLA class II gene selected from the group consisting of any a chain gene of HLA-DR, HLA-DQ, and HLA-DP; and wherein the human portion of the chimeric human/mouse MHC II B polypeptide is encoded by a human HLA class II gene selected from the group consisting of any B chain gene of HLA-DR, HLA-DQ, and HLA-DP. 
Životinja prema zahtjevu 8, naznačena time, da se humani dio kimernog ljudskog/mišjeg MHC-II-a-polipeptida kodira putem humanog gena HLA razreda II odabranog iz skupine koja se sastoji od bilo kojeg gena a-lanca od HLA-DR, HLA-DQ i HLA-DP; te time, da se humani dio kimernog ljudskog/mišjeg MHC-II-B-polipeptida kodira putem humanog gena HLA razreda II odabranog iz skupine koja se sastoji od bilo kojeg gena B-lanca od HLA-DR, HLA-DQ i HLA-DP.
The high-printability coated paper according to one or more of the preceding claims, characterized in that said paper substrate has a grammage comprised between 85 g/m2 and 400 g/m2. 
Premazani papir visoke printabilnosti u skladu s patentnim zahtjevom 1, naznačen time, da je gramatura navedene papirnate podloge u rasponu od 85 g/m2 do 400 g/m2.
4-Methyl-5-(4-pyridazinyl)-2,4-dihydro-3 H -1,2,4-triazole-3-thione, as intermediate in the preparation of the compound of formula (I) according to claim 5. 
-Metil-5-(4-piridazinil)-2,4-dihidro-3H-1,2,4-triazol-3-tion, [image] naznačen time što je međuprodukt u dobivanju spoja formule (I) u skladu s patentnim zahtjevom 5.
The aqueous stoving binder of claim 2 wherein the amine A21 has at least one primary or secondary amino group which are bound to an aliphatic carbon atom, and has from 2 to 40 carbon atoms. 
Vodeno vezivno sredstvo za peći prema zahtjevu 1, naznačeno time, da amin A21 ima najmanje jednu primarnu ili sekundarnu amino-skupinu koja je vezana na alifatski atom ugljika, i ima od 2 do 40 atoma ugljika.
1 and 2, respectively. 
Staffelseestrasse 2, 81477 Munich, DE
Compositions of the present invention where the potassium channel blocker is a mono- or di-aminopyridine active agent are particularly suitable for use in the treatment of a neurological disease that is characterized by demyelination of the central nervous system, more especially multiple sclerosis. 
HR P20130424 T1 PATENTNI ZAHTJEVI Sastav aminopiridina s odgođenim oslobađanjem za upotrebu u postupku tretiranja multiple skleroze, naznačen time da je spomenuti sastav primijenjen dvaput dnevno u dozi od 10 miligrama ili manje aminopiridina.
X is NH optionally substituted by methyl, O, CH2 optionally substituted by fluoro or methyl, or a direct bond; m is 0-2; and n is 0-4. When R1 is phenyl or a 5 or 6 membered heteroaryl ring it may be substituted by up to three substituents selected from halogen, C(1-4)alkyl, C(1-4)alkoxy, trifluoromethoxy, difluoromethoxy, trifluoromethyl and cyano. 
X je izravna veza; m je 0-2; nje0-4;i kada R, je supstituirani fenil ili 5- ili 6-eročlani heteroarilni prsten, isti je supstituiran s do tri supstituenta, koje se neovisno bira između halogena, C(1.alkila, C(,.palkoksi, trifluormetoksi, difluormetoksi, trifluormetila 1 cijano.
applying a first formulation comprising a hair coloring agent and a reducing agent capable of reducing the disulfide bonds in the hair to produce free thiol groups, 
(a) nanošenje prve formulacije koja sadrži sredstvo za bojenje kose i redukcijsko sredstvo u stanju da reducira disulfidne veze u kosi da bi se dobile slobodne tiolne skupine,
The pharmaceutical composition according to any one claims 9 and 20, in the form of controlled release formulation. 
Farmaceutski sastav u skladu s patentnim zahtjevom 9 ili 10, u obliku formulacije s kontroliranim otpuštanjem.
As it has been pointed out in, e.g., “Ring-Opening Polymerization with Expansion in Volume” by William J. Bailey et al, ACS Symposium 59, No. 4; pages 38-59 (1977), most of the critical shrinkage occurs after the gel point in cross-linked materials, or when the monomer-polymer mixture approaches the glass transition point in linear thermoplastic materials. 
Na to je ukazano u npr. "Ring-Opening Polymerization with Expansion in Volume" od William J. Bailey et al, ACS Symposium 59, No. 4, stranice 38-59 (1977), a kritičnog skupljanja se uglavnom događa nakon umrežavanja materijala u obliku gela ili kada smjesa monomer-polimer postiže staklasti prijelazni oblik u linearnom termoplastičnom materijalu.
R1c is a hydrogen atom, a lower alkenyl group or a group of -Q3-A3(R1d)R1e; is a nitrogen atom, or is a methine or 1-vinyl-2-ylidene group optionally substituted by a hydroxyl group, a lower alkyl group or a hydroxy-lower alkyl group; 
c je atom vodika, niža alkenil skupina ili skupina -Q3-A3(R1d)R1e; je atom dušika, ili je metin ili 1-vinil-2-iliden skupina po izboru supstituirana hidroksil skupinom, nižom alkilnom skupinom ili hidroksi-nižom alkilnom skupinom;
According to one embodiment the print medium further comprises a second absorptive layer being in contact with the reverse side of the base layer, and a second topcoat being in contact with the second absorptive layer. 
Tiskovna podloga prema bilo kojem od prethodnih zahtjeva, naznačena time da tiskovna podloga dalje sadrži drugi apsorpcijski sloj u doticaju sa stražnjom stranom osnovnog sloja, i drugi premaz koji je u doticaju s drugim apsorpcijskim slojem.
The pyrazole ester (AX) can be deprotected under acidic conditions using an acid such as TFA in CH2Cl2 to form (AY). 
Pirazol esteru (AX) se može ukloniti zaštitna skupina uz kiselinske uvjete uporabom kiseline poput TFA u CH,Cl> da bi se dobio (AY).
A method of transmitting broadcasting data to a receiver, the method comprising: 
Metoda za prijenos digitalnih video emitiranih podataka u prijamnik, metoda obuhvaća:
is C1-C8-alkyl optionally substituted by OH, halogen C6-C10-aryl optionally substituted by OH, SC1-C8-alkyl, CN, halogen, O-C7-C14-aralkyl, or O-C1-C8-alkyl, a C3-C15-carbocyclic group optionally substituted by O-C7-C14 aralkyl, C3-C15-carbocyclic group, O-C1-C8- alkyl, C2-C8-alkenyl, C2-C8-alkynyl or C1-C8-alkyl, O-C1-C8-alkyl, -SO2-C1-C8-alkyl, a 3- to 12-membered heterocyclic group containing from 1-4 ring nitrogen atoms and optionally containing from 1-4 other heteroatoms selected from the group consisting of oxygen and sulfur, that group being optionally substituted by 3- to 12-membered heterocyclic group containing from 1-4 ring nitrogen atoms and optionally containing from 1-4 other heteroatoms selected from the group consisting of oxygen and sulfur, C7-C14-aralkyl, or C6-C14-aryl optionally substituted by O-C7-C14-aralkyl, or 
je C1-C8-alkil opcijski supstituiran sa OH, halogen, C6-C10-aril opcijski supstituiran sa OH, SC1-C8-alkilom, CN, halogenom, O-C7-C14-aralkilom, ili O-C1-C8-alkilom, C3-C15-karbociklička skupina opcijski supstituirana sa O-C7-C14 aralkilom, C3-C15-karbocikličkom skupinom, O-C1-C8-alkilom, C2-C8-alkenilom, C2-C8-alkinilom ili C1-C8-alkilom, O-C1-C8-alkil, -SO2-C1-C8-alkil, 3- do12-člana heterociklička skupina koja sadrži 1 do 4 prstena dušikovih atoma i opcijski sadrži od 1 do 4 drugih heteroatoma odabranih iz skupine koja obuhvaća kisik i sumpor, a ta skupina se opcijski supstituira sa 3- do 12-članom heterocikličkom skupinom koja sadrži od 1 do 4 prstena dušikovih atoma i opcijski sadrži od 1 do 4 drugih heteroatoma odabranih iz skupine koja obuhvaća kisik i sumpor, C7-C14-aralkil, ili C6-C14-aril opcijski supstituiran sa O-C7-C14-aralkilom, ili
The antibody molecule composition according to claim 37, wherein the antibody is cetuximab or a variant thereof, binding the same epitope as cetuximab, or herceptin. 
Pripravak s molekulom protutijela u skladu s patentnim zahtjevom 37, naznačen time što je protutijelo Cetuksimab, ili njegova varijanta koja se veže na isti epitop kao Cetuksimab, ili herceptin.
The 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivative according to claims 1-2 wherein R2 is halogen. 
Derivat 4-fenil-5-okso-1,4,5,6,7,8-heksahidrokinolina u skladu s patentnim zahtjevima 1-2, gdje R? je halogen.
The process defined in claim 11, wherein the compound of the Formula (I) is purified by HPLC using the following solvent mixtures as eluents: 70:30 dichloromethane/ethyl acetate or 80:20 dichloromethane/tert-butyl methyl ether or 90:10 dichloromethane/acetone. 
Postupak u skladu sa gornjim zahtjevima, naznačen time, da se provodi pročišćavanje dienogesta formule (1) pomoću HPLC uporabom slijedećih mješavina otapala kao eluensa: 70:30 diklorometan/etil acetat ili 80:20 diklorometan/terc-butil metil eter ili 90:10 diklorometan/aceton.